SELE and cancer: We therefore postulated that dPGS-PTX would not only target the tumor microenvironment, by binding P/E-Selectin on endothelial cells and activated platelets, but also the cancer cells population, thus resulting in improved selective targeting, enhanced cellular internalization by receptor-mediated endocytosis and better therapeutic outcome.